Open access
Open access
Powered by Google Translator Translator

Internal Medicine

Opinion: COVID-19 will continue but the end of the pandemic is near.

21 Jan, 2022 | 10:16h | UTC

COVID-19 will continue but the end of the pandemic is near – The Lancet

 

Commentary on Twitter

 


Europe considers new COVID-19 strategy: Accepting the virus.

21 Jan, 2022 | 10:13h | UTC

Europe considers new COVID-19 strategy: Accepting the virus – Associated Press

 


Perspective: Nervous system consequences of COVID-19.

21 Jan, 2022 | 10:10h | UTC

Nervous system consequences of COVID-19 – Science

Related:

Perspective | Post-acute neurological consequences of COVID-19: an unequal burden – “COVID-19 and its neurological consequences particularly burden marginalized communities, and so can only be effectively treated by advancing health equity”.

Review: Counting the neurological cost of COVID-19.

Infection with Covid-19 carries a much higher risk of developing neurological complications than Covid-19 vaccines.

M-A: Frequency of Neurologic Manifestations in COVID-19 – up to one-third of patients (89% hospitalized) experienced at least one neurological manifestation.

Neurological Effects of COVID-19 in Children.

Cohort study: Neurological manifestations of SARS-CoV-2 infection in hospitalized children and adolescents in the UK – “around 1 in 20 of children hospitalized with COVID-19 develop brain or nerve complications linked to the viral infection”.

International Registry: Ischemic and hemorrhagic stroke among critically ill patients with Covid-19.

Short review: Neurological complications of COVID-19.

2 new meta-analysis detail neurologic and psychiatric conditions in COVID-19.

M-A: Encephalitis as Neurological Complication of COVID‐19.

Large study finds 1 in 3 Covid-19 survivors have subsequent mental health and neurological conditionsEight out of ten people hospitalized with COVID-19 develop neurological problems – the most common self-reported symptoms included headache (37%) and anosmia or ageusia (26%).

[Preprint] Frequency of neurological manifestations in COVID-19: a systematic review and meta-analysis of 350 studies – up to one-third of COVID-19 patients analyzed in this review, 89% of whom were hospitalized, experienced at least one neurological manifestation

 

Commentary on Twitter

 


Review: Postdischarge Evaluation for Individuals Hospitalized with COVID-19.

21 Jan, 2022 | 10:08h | UTC

Postdischarge Evaluation for Individuals Hospitalized with COVID-19 – Southern Medical Journal

 


Perioperative guidelines on antiplatelet and anticoagulant agents: 2022 Update.

21 Jan, 2022 | 09:53h | UTC

Perioperative Guidelines on Antiplatelet and Anticoagulant Agents: 2022 Update – Current Anesthesiology Reports

 


Systematic Review: In people with Alzheimer’s disease and vascular dementia with agitation and psychosis, atypical antipsychotics probably reduce agitation slightly (moderate‐certainty evidence) but probably have a negligible effect on psychosis or risk of any adverse event.

21 Jan, 2022 | 09:50h | UTC

Antipsychotics for agitation and psychosis in people with Alzheimer’s disease and vascular dementia – Cochrane Library

Summary: Do antipsychotic medicines reduce  agitated behaviour and psychotic symptoms in people with Alzheimer’s disease and vascular dementia? – Cochrane Library

 


Sleeping on the LEFT side seems to be associated with reduced nocturnal acid exposure compared with supine and right lateral decubitus positions.

21 Jan, 2022 | 09:45h | UTC

Associations Between Sleep Position and Nocturnal Gastroesophageal Reflux: A Study Using Concurrent Monitoring of Sleep Position and Esophageal pH and Impedance – American Journal of Gastroenterology (link to abstract – $ for full-text)

 


Review: Diagnostic evaluation of gastric motor and sensory disorders.

21 Jan, 2022 | 09:42h | UTC

Diagnostic Evaluation of Gastric Motor and Sensory Disorders – American Journal of Gastroenterology

 


M-A: No difference in outcomes with Beta-lactam monotherapy vs. combination therapy for bloodstream infections or pneumonia due to P. aeruginosa.

21 Jan, 2022 | 09:37h | UTC

Beta-lactam monotherapy or combination therapy for bloodstream infections or pneumonia due to P. aeruginosa: a meta-analysis – International Journal of Antimicrobial Agents (link to abstract – $ for full-text)

 


Cluster Randomized Trial: A multifactorial falls prevention program in UK care homes reduced fall rates among older people and was cost effective.

21 Jan, 2022 | 09:21h | UTC

Multifactorial falls prevention programme compared with usual care in UK care homes for older people: multicentre cluster randomised controlled trial with economic evaluation – The BMJ

News Release: Falls in care homes can be significantly reduced with intervention, says new study – University of Nottingham

 

Commentary on Twitter

 


Booster longevity: Data reveals how long a third shot protects.

20 Jan, 2022 | 09:33h | UTC

Booster longevity: Data reveals how long a third shot protects – NPR

Original Report: SARS-CoV-2 variants of concern and variants under investigation in England – U.K. Health Security Agency

 


A populational-based retrospective cohort study in Qatar showed a reduced risk of Covid-19 breakthrough infections with the Moderna vs. the Pfizer–BioNTech vaccine.

20 Jan, 2022 | 09:30h | UTC

Effectiveness of mRNA-1273 and BNT162b2 Vaccines in Qatar – New England Journal of Medicine

 

Commentary on Twitter

 


Milder disease with Omicron: is it the virus or the pre-existing immunity?

20 Jan, 2022 | 09:28h | UTC

Milder disease with Omicron: is it the virus or the pre-existing immunity? – Nature Reviews Immunology

 


Short Review: Fluvoxamine for symptomatic outpatients with COVID-19.

20 Jan, 2022 | 09:25h | UTC

Fluvoxamine for symptomatic outpatients with COVID-19 – Canadian Medical Association Journal

Related:

Fluvoxamine for Covid-19: What Prescribers and Pharmacists Need to Know.

Fluvoxamine for the early treatment of SARS-CoV-2 Infection: a review of current evidence.

RCT: Early treatment with fluvoxamine reduced the risk of emergency care and hospitalization among patients with COVID-19.

[Preprint] RCT: Fluvoxamine reduced the risk for ER visits and hospitalization among patients with Covid-19.

Opinion | Could this be our first effective, inexpensive, widely available outpatient treatment for COVID-19? (It’s fluvoxamine).

Preliminary study shows fluvoxamine may reduce clinical deterioration in outpatients with symptomatic COVID-19

 


Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis.

20 Jan, 2022 | 09:17h | UTC

Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis – The Lancet

News Release: An estimated 1.2 million people died in 2019 from antibiotic-resistant bacterial infections, more deaths than HIV/AIDS or malaria – The Lancet

Editorial: Antimicrobial resistance: time to repurpose the Global Fund – The Lancet

Commentary: Antimicrobial resistance now a leading cause of death worldwide, study finds – The Guardian

 

Commentary on Twitter

 


RCT: Among patients with recurrent Clostridioides difficile infection, the use of SER-109, an oral microbiome therapy, reduced recurrence rate compared to placebo (12% vs. 40%).

20 Jan, 2022 | 09:11h | UTC

SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection – New England Journal of Medicine (link to abstract – $ for full-text)

 


Meta-analysis of randomized controlled trials: Drug treatment for panic disorder with or without agoraphobia.

20 Jan, 2022 | 09:06h | UTC

Drug treatment for panic disorder with or without agoraphobia: systematic review and network meta-analysis of randomised controlled trials – The BMJ

 


Study shows that the retinal age gap might be a potential biomarker of aging linked to increased mortality risk.

20 Jan, 2022 | 09:04h | UTC

Retinal age gap as a predictive biomarker for mortality risk – British Journal of Ophthalmology (link to abstract – $ for full-text)

News Release: Difference between retina’s biological age and person’s real age linked to heightened death risk – BMJ

 

Commentary on Twitter

 


M-A: the accuracy of serological tests to support the diagnosis of celiac disease.

20 Jan, 2022 | 09:02h | UTC

Systematic review with meta-analysis: the accuracy of serological tests to support the diagnosis of coeliac disease – Alimentary Pharmacology & Therapeutics

 


Systematic Review: Prevalence, incidence and survival of heart failure.

20 Jan, 2022 | 09:00h | UTC

Prevalence, incidence and survival of heart failure: a systematic review – Heart

 


Review: Evaluating the patient with a pulmonary nodule.

20 Jan, 2022 | 08:56h | UTC

Evaluating the Patient With a Pulmonary Nodule: A Review – JAMA (free for a limited period)

Author Interview: Evaluation and Management of Patients With Pulmonary Nodules

 


Review: Diagnosis and treatment of polycystic ovary syndrome.

20 Jan, 2022 | 08:54h | UTC

Diagnosis and Treatment of Polycystic Ovary Syndrome – JAMA (free for a limited period)

 


Consensus recommendations on managing the selected comorbidities including cardiovascular disease, osteoporosis, and interstitial lung disease in rheumatoid arthritis.

20 Jan, 2022 | 08:52h | UTC

Consensus recommendations on managing the selected comorbidities including cardiovascular disease, osteoporosis, and interstitial lung disease in rheumatoid arthritis – Medicine

 


Consensus Statement: Exercise/physical activity in individuals with Type 2 Diabetes.

20 Jan, 2022 | 08:51h | UTC

Exercise/Physical Activity in Individuals with Type 2 Diabetes: A Consensus Statement from the American College of Sports Medicine – Medicine & Science in Sports & Exercise

 

Commentary from the author on Twitter

 


M-A: Association of Sodium-Glucose Cotransporter 2 Inhibitors with cardiovascular outcomes in patients with Type 2 Diabetes and other risk factors for cardiovascular disease.

20 Jan, 2022 | 08:42h | UTC

Association of Sodium-Glucose Cotransporter 2 Inhibitors With Cardiovascular Outcomes in Patients With Type 2 Diabetes and Other Risk Factors for Cardiovascular Disease: A Meta-analysis – JAMA Network Open

 

Commentary on Twitter

 


Stay Updated in Your Specialty

No spam, just news.